Synergistic Antitumor Effect Of Naproxen And Sorafenib In Hepatocellular Carcinoma
Akar, E.; Unsal Beyge, S.; Kahraman, D. C.
Show abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadliest cancer types in the world. Due to the inevitable development of resistance to classical chemotherapy and current targeted therapies, combination therapy became an important strategy. Recently drug repurposing studies have emphasized the potential of non-steroidal anti-inflammatory drugs (NSAIDs) in exhibiting anti-tumor activities in different cancer types, including HCC. In this study we explored the synergistic bioactivity of naproxen in combination with sorafenib in HCC cell lines. Network reconstruction analysis, performed to identify key factors mediating the synergistic therapeutic effects of sorafenib and naproxen revealed apoptosis pathways enriched in both sorafenib and naproxen networks. CAPN2 emerged as the common gene shared between the two networks. In vitro studies on Huh7 and Mahlavu cells revealed that induction of apoptosis was associated mainly with the PI3K/AKT pathway inhibition. Furthermore, combined treatment of naproxen and sorafenib led to the downregulation of CAPN2 expression, suggesting a potential link to apoptosis and PI3K/AKT pathway regulation, which needs further investigation. In conclusion, combining sorafenib with naproxen presents a promising strategy with potential synergistic therapeutic benefits in HCC.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AATF Inhibition Exerts Antiangiogenic Effects AgainstHuman Hepatocellular Carcinoma 96%
- miR-100-5p downregulates mTOR to suppress the proliferation, migration and invasion of prostate cancer cells 95%
- Systems biomedicine of primary and metastatic colorectal cancer reveals potential therapeutic targets 95%
Similar papers in this journal
- P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib 96%
- A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin 96%
- Application of non-invasive low-intensity pulsed electric field with thermal cycling-hyperthermia for synergistically enhanced anticancer effect of chlorogenic acid on PANC-1 cells 96%
Similar papers in this journal
- Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer 94%
- Protein profiling of WERI RB1 and etoposide resistant WERI ETOR reveals new insights into topoisomerase inhibitor resistance in retinoblastoma 94%
- A small molecule that promotes cellular senescence prevents fibrogenesis and tumorigenesis in vitro 94%
Similar papers in this journal
- Tegaserod maleate suppresses the growth of gastric cancer in vivo and in vitro by targeting MEK1/2 95%
- Synthetic lethality screening identifies FDA-approved drugs that overcome ATP7B-mediated tolerance of tumor cells to cisplatin 94%
- The differential metabolic signature of breast cancer cellular response to olaparib treatment 94%
Similar papers in this journal
- Augmented efficacy of uttroside B over sorafenib in a murine model of human hepatocellular carcinoma 95%
- Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma 94%
- Ursolic acid inhibits cell migration and promotes JNK-dependent lysosomal associated cell death in Glioblastoma multiforme cells 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.